摘要
目的:探讨孟鲁司特钠辅助治疗咳嗽变异性哮喘的疗效及对血清炎性因子水平的影响。方法:选择2015年11月至2017年8月肇庆市第一人民医院收治的咳嗽变异性哮喘患者130例作为研究对象,以数字奇偶法分为观察组和对照组,每组65例。对照组患者沙丁胺醇气雾剂治疗,观察组患者在对照组的基础上加用孟鲁司特钠治疗。观察两组患者的临床疗效、肺功能恢复情况及血清炎性因子水平。结果:观察组患者的总有效率为98.46%(64/65),明显高于对照组的80.00%(52/65),差异有统计学意义(P<0.05);治疗后,两组患者1 s用力呼气容积、1 s用力呼气容积占用力肺活量百分比明显高于治疗前,且观察组患者明显高于对照组,差异均有统计学意义(P<0.05);治疗后,两组患者白细胞介素6、肿瘤坏死因子α水平明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。结论:孟鲁司特钠联合沙丁胺醇气雾剂治疗咳嗽变异性哮喘的疗效显著,可改善患者肺功能,降低血清炎性因子水平,改善预后。
OBJECTIVE： To probe into the efficacy of montelukast sodium in adjuvant treatment of cough variant asthma and its effects on serum inflammatory factors. METHODS： 130 patients with cough variant asthma admitted into the First People＇s Hospital of Zhaoqing from Nov. 2015 to Aug. 2017 were selected and divided into observation group and control group via odd-even method,with 65 cases in each. The control group was treated with salbutamol aerosol,while the observation group was given montelukast sodium combined with salbutamol aerosol. Clinical efficacy,recovery of pulmonary function and serum inflammatory factors levels of both groups were observed. RESULTS： The total effective rate of observation group was 98. 46%（ 64/65）,which was significantly higher than that of the control group（ 80. 00%,52/65）,with statistically significant difference（ P〈0. 05）; after treatment,the forced expiratory volume in 1 s（ FEV1）and FEV1/forced vital capacity（ FVC） of both groups were significantly higher than those of before treatment,and those of observation group were significantly higher than the control group,with statistically significant differences（ P〈0. 05）;after treatment,the interleukin-6（ IL-6） and tumor necrosis factor α（ TNF-α） levels of both groups were significantly lower than those of before treatment,and those of observation group were significantly lower than the control group,with statistically significant differences（ P〈0. 05）. CONCLUSIONS： The efficacy of montelukast sodium combined with salbutamol aerosol in treatment of cough variant asthma is remarkable,which can significantly improve patients＇ pulmonary function,reduce serum inflammatory factors level and promote prognoses.
作者
容令新
莫火弟
陈智锋
RONG Lingxin1, MO Huodi1, CHEN Zhifeng2(1. Dept. of Pharmacy, the First People＇ s Hospital of Zhaoqing, Guangdong Zhaoqing 526040, China; 2. Dept. of Pediatric, the First People＇ s Hospital of Zhaoqing, Guangdong Zhaoqing 526040, Chin)
出处
《中国医院用药评价与分析》
2018年第5期629-630,633,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
孟鲁司特钠
咳嗽变异性哮喘
炎性因子
Montelstra sodium
Cough variant asthma
Inflammatory factors
